Please login to the form below

Not currently logged in
Email:
Password:

Bioverativ

This page shows the latest Bioverativ news and features for those working in and with pharma, biotech and healthcare.

Sanofi’s sutimlimab set for filing in rare autoimmune anaemia next year

Sanofi’s sutimlimab set for filing in rare autoimmune anaemia next year

Sanofi acquired rights to sutimlimab as part of its $11.6bn takeover of Bioverativ last year under former CEO Olivier Brandicourt, and has been billed as one of the most promising

Latest news

More from news
Approximately 3 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Biogen's spin-out, Bioverativ, had not even got past its first anniversary as a Nasdaq-listed company before being snapped up by Sanofi for $11.6bn (although this is not ... only with its rare disease focus but also enhances its portfolio of products for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Industry appointments Industry appointments

    Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... The firm has managed to poach Bioverativ’s senior executive Rogerio Vivaldi (pictured

  • Voyager Therapeutics appoints Matthew Ottmer as chief operating officer Voyager Therapeutics appoints Matthew Ottmer as chief operating officer

    the chief executive officer and president of Syntonix Pharmaceuticals - a wholly owned subsidiary of Biogen, now Bioverativ - and vice president of global operations.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics